

# Morten HÃ¸yer

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1729209/publications.pdf>

Version: 2024-02-01

158  
papers

8,285  
citations

71004

43  
h-index

58552

86  
g-index

158  
all docs

158  
docs citations

158  
times ranked

8398  
citing authors

#	ARTICLE	IF	CITATIONS
1	A phase I/II study of acute and late physician assessed and patient-reported morbidity following whole pelvic radiation in high-risk prostate cancer patients. <i>Acta Oncologica</i> , 2022, 61, 179-184.	0.8	8
2	Proton therapy for early breast cancer patients in the DBCG proton trial: planning, adaptation, and clinical experience from the first 43 patients. <i>Acta Oncologica</i> , 2022, 61, 223-230.	0.8	5
3	Clinical outcomes after stereotactic ablative radiotherapy in locally advanced cholangiocarcinoma. <i>Acta Oncologica</i> , 2022, 61, 197-201.	0.8	2
4	"No time to die" BIGART is back. The 20th Acta Oncologica Symposium "BIGART 2021. <i>Acta Oncologica</i> , 2022, 61, 117-119.	0.8	1
5	Spot-scanning proton therapy for targets with adjacent cardiac implantable electronic devices "Strategies for breast and head & neck cancer. <i>Physics and Imaging in Radiation Oncology</i> , 2022, 21, 66-71.	1.2	1
6	A year of pandemic for European particle radiotherapy: A survey on behalf of EPTN working group. <i>Clinical and Translational Radiation Oncology</i> , 2022, 34, 1-6.	0.9	2
7	Research in radiation oncology and the Covid-19 pandemic. <i>Acta Oncologica</i> , 2021, 60, 275-276.	0.8	2
8	Response to: "Comments on "Temporal lobe sparing radiotherapy with photons or protons for cognitive function preservation in paediatric craniopharyngioma" by Toussaint, et al.: Prior similar field arrangement work and a need for variable RBE Use". <i>Radiotherapy and Oncology</i> , 2021, 158, 330-331.	0.3	1
9	Androgen Deprivation Therapy Combined With Particle Therapy for Prostate Cancer: A Systematic Review. <i>Frontiers in Oncology</i> , 2021, 11, 695647.	1.3	0
10	Risk of Cardiac Implantable Electronic Device Malfunctioning During Pencil Beam Proton Scanning in an In Vitro Setting. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 111, 186-195.	0.4	6
11	Uniform versus non-uniform dose prescription for proton stereotactic body radiotherapy of liver tumors investigated by extensive motion-including treatment simulations. <i>Physics in Medicine and Biology</i> , 2021, 66, 205009.	1.6	3
12	Real-time dose-guidance in radiotherapy: proof of principle. <i>Radiotherapy and Oncology</i> , 2021, 164, 175-182.	0.3	8
13	Does the uncertainty in relative biological effectiveness affect patient treatment in proton therapy?. <i>Radiotherapy and Oncology</i> , 2021, 163, 177-184.	0.3	38
14	Effect of stereotactic body radiotherapy on regional metabolic liver function investigated in patients by dynamic [18F]FDG PET/CT. <i>Radiation Oncology</i> , 2021, 16, 192.	1.2	2
15	Temporal lobe sparing radiotherapy with photons or protons for cognitive function preservation in paediatric craniopharyngioma. <i>Radiotherapy and Oncology</i> , 2020, 142, 140-146.	0.3	15
16	Isotoxic dose prescription level strategies for stereotactic liver radiotherapy: the price of dose uniformity. <i>Acta Oncologica</i> , 2020, 59, 558-564.	0.8	7
17	Nonsurgical Salvage Local Therapies for Radiorecurrent Prostate Cancer: A Systematic Review and Meta-analysis. <i>European Urology Oncology</i> , 2020, 3, 183-197.	2.6	46
18	Simulated multileaf collimator tracking for stereotactic liver radiotherapy guided by kilovoltage intrafraction monitoring: Dosimetric gain and target overdose trends. <i>Radiotherapy and Oncology</i> , 2020, 144, 93-100.	0.3	8

#	ARTICLE	IF	CITATIONS
19	Is there a Nordic solution for the "proton-problem"? Acta Oncologica, 2020, 59, 1137-1138.	0.8	0
20	Radionecrosis and cellular changes in small volume stereotactic brain radiosurgery in a porcine model. Scientific Reports, 2020, 10, 16223.	1.6	8
21	A Nordic-Baltic perspective on indications for proton therapy with strategies for identification of proper patients. Acta Oncologica, 2020, 59, 1157-1163.	0.8	6
22	Defining oligometastatic disease from a radiation oncology perspective: An ESTRO-ASTRO consensus document. Radiotherapy and Oncology, 2020, 148, 157-166.	0.3	352
23	Cognitive impairment following radiation to hippocampus and other brain structures in adults with primary brain tumours. Radiotherapy and Oncology, 2020, 148, 1-7.	0.3	32
24	Oligorecurrent prostate cancer limited to lymph nodes: getting our ducks in a row. World Journal of Urology, 2019, 37, 2607-2613.	1.2	18
25	Radiation doses to brain substructures associated with cognition in radiotherapy of pediatric brain tumors. Acta Oncologica, 2019, 58, 1457-1462.	0.8	13
26	Simulated real-time dose reconstruction for moving tumors in stereotactic liver radiotherapy. Medical Physics, 2019, 46, 4738-4748.	1.6	9
27	First clinical real-time motion-including tumor dose reconstruction during radiotherapy delivery. Radiotherapy and Oncology, 2019, 139, 66-71.	0.3	21
28	BIGART 2019 "adapting to the future. Acta Oncologica, 2019, 58, 1323-1327.	0.8	1
29	Patient specific outcomes of charged particle therapy for hepatocellular carcinoma "A systematic review and quantitative analysis. Radiotherapy and Oncology, 2019, 132, 127-134.	0.3	19
30	Long-term cognitive dysfunction after radiation therapy for primary brain tumors. Acta Oncologica, 2019, 58, 745-752.	0.8	29
31	A Prospective Cohort Study of Gated Stereotactic Liver Radiation Therapy Using Continuous Internal Electromagnetic Motion Monitoring. International Journal of Radiation Oncology Biology Physics, 2018, 101, 366-375.	0.4	43
32	Limited post-chemotherapy retroperitoneal resection of residual tumour in non-seminomatous testicular cancer: complications, outcome and quality of life. Acta Oncologica, 2018, 57, 1084-1093.	0.8	11
33	Inter-institutional analysis demonstrates the importance of lower than previously anticipated dose regions to prevent late rectal bleeding following prostate radiotherapy. Radiotherapy and Oncology, 2018, 127, 88-95.	0.3	14
34	Automatic online and real-time tumour motion monitoring during stereotactic liver treatments on a conventional linac by combined optical and sparse monoscopic imaging with kilovoltage x-rays (COSMIK). Physics in Medicine and Biology, 2018, 63, 055012.	1.6	20
35	Long-term urodynamic findings following radical prostatectomy and salvage radiotherapy. Scandinavian Journal of Urology, 2018, 52, 20-26.	0.6	9
36	Validation of fast motion-including dose reconstruction for proton scanning therapy in the liver. Physics in Medicine and Biology, 2018, 63, 225021.	1.6	5

#	ARTICLE	IF	CITATIONS
37	Radiation dose constraints for organs at risk in neuro-oncology; the European Particle Therapy Network consensus. <i>Radiotherapy and Oncology</i> , 2018, 128, 26-36.	0.3	112
38	Geometric and dosimetric comparison of four intrafraction motion adaptation strategies for stereotactic liver radiotherapy. <i>Physics in Medicine and Biology</i> , 2018, 63, 145010.	1.6	16
39	Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma: Current Trends and Controversies. <i>Technology in Cancer Research and Treatment</i> , 2018, 17, 153303381879021.	0.8	53
40	Metastasis directed therapy for liver and lung metastases from colorectal cancerâ€”A populationâ€based study. <i>International Journal of Cancer</i> , 2018, 143, 3218-3226.	2.3	17
41	Nomogram based overall survival prediction in stereotactic body radiotherapy for oligo-metastatic lung disease. <i>Radiotherapy and Oncology</i> , 2017, 123, 182-188.	0.3	55
42	Cone beam CT-based set-up strategies with and without rotational correction for stereotactic body radiation therapy in the liver. <i>Acta OncolÃ³gica</i> , 2017, 56, 860-866.	0.8	17
43	2-[ <sup>18</sup> F]fluoro-2-deoxy-d-galactose positron emission tomography guided functional treatment planning of stereotactic body radiotherapy of liver tumours. <i>Physics and Imaging in Radiation Oncology</i> , 2017, 1, 28-33.	1.2	8
44	Toxicity of concurrent stereotactic radiotherapy and targeted therapy or immunotherapy: A systematic review. <i>Cancer Treatment Reviews</i> , 2017, 53, 25-37.	3.4	169
45	Validation of genetic predictors of late radiation-induced morbidity in prostate cancer patients. <i>Acta OncolÃ³gica</i> , 2017, 56, 1514-1521.	0.8	5
46	A phase I study on stereotactic body radiotherapy of liver metastases based on functional treatment planning using positron emission tomography with 2- <sup>18</sup> Ffluoro-2-deoxy- <sup>3</sup> H-galactose. <i>Acta OncolÃ³gica</i> , 2017, 56, 1614-1620.	0.8	7
47	Spatial rectal dose/volume metrics predict patient-reported gastro-intestinal symptoms after radiotherapy for prostate cancer. <i>Acta OncolÃ³gica</i> , 2017, 56, 1507-1513.	0.8	23
48	Radiation Therapy for Liver Metastases: Clinical Data. , 2017, , 245-256.		0
49	Late urinary morbidity and quality of life after radical prostatectomy and salvage radiotherapy for prostate cancer. <i>Scandinavian Journal of Urology</i> , 2017, 51, 457-463.	0.6	8
50	Rethink radiotherapy â€” BIGART 2017. <i>Acta OncolÃ³gica</i> , 2017, 56, 1341-1352.	0.8	6
51	ESTRO ACROP consensus guideline on implementation and practice of stereotactic body radiotherapy for peripherally located early stage non-small cell lung cancer. <i>Radiotherapy and Oncology</i> , 2017, 124, 11-17.	0.3	230
52	Simultaneous acquisition of 4D ultrasound and wireless electromagnetic tracking for <i>in-vivo</i> accuracy validation. <i>Current Directions in Biomedical Engineering</i> , 2017, 3, 75-78.	0.2	5
53	Re-irradiation with stereotactic body radiation therapy (SBRT). <i>Chinese Clinical Oncology</i> , 2017, 6, S15-S15.	0.4	15
54	A biological modeling based comparison of two strategies for adaptive radiotherapy of urinary bladder cancer. <i>Acta OncolÃ³gica</i> , 2016, 55, 1009-1015.	0.8	5

#	ARTICLE	IF	CITATIONS
55	198PD: Nomogram for predicting overall survival after stereotactic body radiotherapy for pulmonary metastases: Development and external validation. <i>Journal of Thoracic Oncology</i> , 2016, 11, S143.	0.5	2
56	The potential of MRI-guided online adaptive re-optimisation in radiotherapy of urinary bladder cancer. <i>Radiotherapy and Oncology</i> , 2016, 118, 154-159.	0.3	49
57	Urinary bladder dose-response relationships for patient-reported genitourinary morbidity domains following prostate cancer radiotherapy. <i>Radiotherapy and Oncology</i> , 2016, 119, 117-122.	0.3	23
58	Time-Resolved Intrafraction Target Translations and Rotations During Stereotactic Liver Radiation Therapy: Implications for Marker-based Localization Accuracy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 95, 802-809.	0.4	42
59	Ten- and 15-yr Prostate Cancer-specific Mortality in Patients with Nonmetastatic Locally Advanced or Aggressive Intermediate Prostate Cancer, Randomized to Lifelong Endocrine Treatment Alone or Combined with Radiotherapy: Final Results of The Scandinavian Prostate Cancer Group-7. <i>European Urology</i> , 2016, 70, 684-691.	0.9	71
60	Salvage radiation therapy following radical prostatectomy. A national Danish study. <i>Acta Oncologica</i> , 2016, 55, 598-603.	0.8	17
61	Fiducial marker guided stereotactic liver radiotherapy: Is a time delay between marker implantation and planning CT needed?. <i>Radiotherapy and Oncology</i> , 2016, 121, 75-78.	0.3	24
62	A randomised phase II trial of Stereotactic Ablative Fractionated radiotherapy versus Radiosurgery for Oligometastatic Neoplasia to the lung (TROG 13.01 SAFRON II). <i>BMC Cancer</i> , 2016, 16, 183.	1.1	34
63	Metabolic liver function after stereotactic body radiation therapy for hepatocellular carcinoma. <i>Acta Oncologica</i> , 2016, 55, 886-891.	0.8	16
64	Survival and prognostic factors in 321 patients treated with stereotactic body radiotherapy for oligo-metastases. <i>Radiotherapy and Oncology</i> , 2015, 114, 155-160.	0.3	100
65	Intra-fractional bladder motion and margins in adaptive radiotherapy for urinary bladder cancer. <i>Acta Oncologica</i> , 2015, 54, 1461-1466.	0.8	26
66	The usability of a 15-gene hypoxia classifier as a universal hypoxia profile in various cancer cell types. <i>Radiotherapy and Oncology</i> , 2015, 116, 346-351.	0.3	26
67	The evolution of radiotherapy techniques in the management of prostate cancer. <i>Acta Oncologica</i> , 2015, 54, 821-824.	0.8	8
68	Survival and prognostic factors in patients treated with stereotactic radiotherapy for brain metastases. <i>Acta Oncologica</i> , 2015, 54, 107-114.	0.8	12
69	Biology-guided adaptive radiotherapy (BiGART) is progressing towards clinical reality. <i>Acta Oncologica</i> , 2015, 54, 1245-1250.	0.8	10
70	Long-term results of a prospective phase II trial of medically inoperable stage I NSCLC treated with SBRT - the Nordic experience. <i>Acta Oncologica</i> , 2015, 54, 1096-1104.	0.8	66
71	Relationships between dose to the gastro-intestinal tract and patient-reported symptom domains after radiotherapy for localized prostate cancer. <i>Acta Oncologica</i> , 2015, 54, 1326-1334.	0.8	32
72	Respiratory gating based on internal electromagnetic motion monitoring during stereotactic liver radiation therapy: First results. <i>Acta Oncologica</i> , 2015, 54, 1445-1452.	0.8	43

#	ARTICLE	IF	CITATIONS
73	An image-based method to quantify biomechanical properties of the rectum in radiotherapy of prostate cancer. <i>Acta Oncologica</i> , 2015, 54, 1335-1342.	0.8	11
74	Quality of venous thromboembolism diagnoses among prostate cancer patients in the Danish National Registry of Patients. <i>Clinical Epidemiology</i> , 2014, 6, 351.	1.5	13
75	Fast motion-including dose error reconstruction for VMAT with and without MLC tracking. <i>Physics in Medicine and Biology</i> , 2014, 59, 7279-7296.	1.6	22
76	A comparison of morbidity following conformal versus intensity-modulated radiotherapy for urinary bladder cancer. <i>Acta Oncologica</i> , 2014, 53, 1321-1328.	0.8	31
77	Pathophysiology of late anorectal dysfunction following external beam radiotherapy for prostate cancer. <i>Acta Oncologica</i> , 2014, 53, 1398-1404.	0.8	10
78	Normal tissue sparing in a phase II trial on daily adaptive plan selection in radiotherapy for urinary bladder cancer. <i>Acta Oncologica</i> , 2014, 53, 997-1004.	0.8	59
79	An adaptive radiotherapy planning strategy for bladder cancer using deformation vector fields. <i>Radiotherapy and Oncology</i> , 2014, 112, 371-375.	0.3	15
80	Kilovoltage intrafraction motion monitoring and target dose reconstruction for stereotactic volumetric modulated arc therapy of tumors in the liver. <i>Radiotherapy and Oncology</i> , 2014, 111, 424-430.	0.3	47
81	Evaluation of an application for intensity-based deformable image registration and dose accumulation in radiotherapy. <i>Acta Oncologica</i> , 2014, 53, 1329-1336.	0.8	26
82	Development and validation of a scoring system for late anorectal side-effects in patients treated with radiotherapy for prostate cancer. <i>Radiotherapy and Oncology</i> , 2014, 111, 94-99.	0.3	23
83	Variations in magnitude and directionality of respiratory target motion throughout full treatment courses of stereotactic body radiotherapy for tumors in the liver. <i>Acta Oncologica</i> , 2013, 52, 1437-1444.	0.8	47
84	Three-dimensional, Time-Resolved, Intrafraction Motion Monitoring Throughout Stereotactic Liver Radiation Therapy on a Conventional Linear Accelerator. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 86, 190-197.	0.4	65
85	Adaptive plan selection vs. re-optimisation in radiotherapy for bladder cancer: A dose accumulation comparison. <i>Radiotherapy and Oncology</i> , 2013, 109, 457-462.	0.3	68
86	Biology-guided adaptive radiotherapy (BiGART) – more than a vision?. <i>Acta Oncologica</i> , 2013, 52, 1243-1247.	0.8	23
87	Degradation of target coverage due to inter-fraction motion during intensity-modulated proton therapy of prostate and elective targets. <i>Acta Oncologica</i> , 2013, 52, 521-527.	0.8	43
88	Time-resolved dose reconstruction by motion encoding of volumetric modulated arc therapy fields delivered with and without dynamic multi-leaf collimator tracking. <i>Acta Oncologica</i> , 2013, 52, 1497-1503.	0.8	13
89	Time-resolved dose distributions to moving targets during volumetric modulated arc therapy with and without dynamic MLC tracking. <i>Medical Physics</i> , 2013, 40, 111723.	1.6	24
90	Validity of the Danish National Registry of Patients for chemotherapy reporting among colorectal cancer patients is high. <i>Clinical Epidemiology</i> , 2013, 5, 327.	1.5	22

#	ARTICLE	IF	CITATIONS
91	An international survey on liver metastases radiotherapy. <i>Acta Oncologica</i> , 2012, 51, 568-574.	0.8	35
92	Stereotactic body radiation therapy – A discipline with Nordic origin and profile. <i>Acta Oncologica</i> , 2012, 51, 564-567.	0.8	12
93	Radiation therapy for liver metastases. <i>Current Opinion in Supportive and Palliative Care</i> , 2012, 6, 97-102.	0.5	13
94	Radiotherapy for Liver Metastases: A Review of Evidence. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 82, 1047-1057.	0.4	172
95	On-Line Use of Three-Dimensional Marker Trajectory Estimation From Cone-Beam Computed Tomography Projections for Precise Setup in Radiotherapy for Targets With Respiratory Motion. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 83, e145-e151.	0.4	26
96	Intratumoral neutrophils and plasmacytoid dendritic cells indicate poor prognosis and are associated with pSTAT3 expression in AJCC stage I/II melanoma. <i>Cancer</i> , 2012, 118, 2476-2485.	2.0	219
97	Deformable image registration for contour propagation from CT to cone-beam CT scans in radiotherapy of prostate cancer. <i>Acta Oncologica</i> , 2011, 50, 918-925.	0.8	118
98	Plan robustness in proton beam therapy of a childhood brain tumour. <i>Acta Oncologica</i> , 2011, 50, 791-796.	0.8	9
99	Clinical validation of a 4D-CT based method for lung ventilation measurement in phantoms and patients. <i>Acta Oncologica</i> , 2011, 50, 897-907.	0.8	18
100	Normal liver tissue sparing by intensity-modulated proton stereotactic body radiotherapy for solitary liver tumours. <i>Acta Oncologica</i> , 2011, 50, 823-828.	0.8	52
101	Robust automatic segmentation of multiple implanted cylindrical gold fiducial markers in cone-beam CT projections. <i>Medical Physics</i> , 2011, 38, 6351-6361.	1.6	39
102	Particle Therapy – A next logical step in the improvement of radiotherapy. <i>Acta Oncologica</i> , 2011, 50, 741-744.	0.8	12
103	Faecal incontinence following radiotherapy for prostate cancer: A systematic review. <i>Radiotherapy and Oncology</i> , 2011, 98, 145-153.	0.3	41
104	Advances in radiotherapy: from 2D to 4D. <i>Cancer Imaging</i> , 2011, 11, S145-S152.	1.2	5
105	Survival in patients with synchronous liver metastases in central and northern Denmark, 1998 to 2009. <i>Clinical Epidemiology</i> , 2011, 3 Suppl 1, 11.	1.5	9
106	NTCP modelling of lung toxicity after SBRT comparing the universal survival curve and the linear quadratic model for fractionation correction. <i>Acta Oncologica</i> , 2011, 50, 518-527.	0.8	31
107	Phase I/II study on docetaxel, gemcitabine and prednisone in castrate refractory metastatic prostate cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2010, 66, 295-301.	1.1	9
108	Stereotactic body radiotherapy for unresectable cholangiocarcinoma. <i>Radiotherapy and Oncology</i> , 2010, 94, 47-52.	0.3	159



#	ARTICLE	IF	CITATIONS
109	Temporary sacral nerve stimulation for faecal incontinence following pelvic radiotherapy. <i>Radiotherapy and Oncology</i> , 2010, 97, 108-112.	0.3	15
110	A comparison of three different adaptive strategies in image-guided radiotherapy of bladder cancer. <i>Acta Oncologica</i> , 2010, 49, 1069-1076.	0.8	59
111	Biology-guided adaptive radiation therapy " presence or future?. <i>Acta Oncologica</i> , 2010, 49, 884-887.	0.8	17
112	Inter- and intrafractional localisation errors in cone-beam CT guided stereotactic radiation therapy of tumours in the liver and lung. <i>Acta Oncologica</i> , 2010, 49, 1177-1183.	0.8	58
113	A study of image-guided radiotherapy of bladder cancer based on lipiodol injection in the bladder wall. <i>Acta Oncologica</i> , 2010, 49, 1109-1115.	0.8	45
114	Propagation of target and organ at risk contours in radiotherapy of prostate cancer using deformable image registration. <i>Acta Oncologica</i> , 2010, 49, 1023-1032.	0.8	83
115	Imaging of normal lung, liver and parotid gland function for radiotherapy. <i>Acta Oncologica</i> , 2010, 49, 997-1011.	0.8	28
116	Evaluation of adaptive radiotherapy of bladder cancer by image-based tumour control probability modelling. <i>Acta Oncologica</i> , 2010, 49, 1045-1051.	0.8	22
117	A method to individualize adaptive planning target volumes for deformable targets. <i>Physics in Medicine and Biology</i> , 2009, 54, 7121-7133.	1.6	18
118	Outcome in a Prospective Phase II Trial of Medically Inoperable Stage I Non-Small-Cell Lung Cancer Patients Treated With Stereotactic Body Radiotherapy. <i>Journal of Clinical Oncology</i> , 2009, 27, 3290-3296.	0.8	780
119	Macrophage Markers in Serum and Tumor Have Prognostic Impact in American Joint Committee on Cancer Stage I/II Melanoma. <i>Journal of Clinical Oncology</i> , 2009, 27, 3330-3337.	0.8	255
120	Half body irradiation of patients with multiple bone metastases: A phase II trial. <i>Acta Oncologica</i> , 2009, 48, 556-561.	0.8	27
121	The normal tissue sparing obtained with simultaneous treatment of pelvic lymph nodes and bladder using intensity-modulated radiotherapy. <i>Acta Oncologica</i> , 2009, 48, 238-244.	0.8	42
122	Co-morbidity index predicts for mortality after stereotactic body radiotherapy for medically inoperable early-stage non-small cell lung cancer. <i>Radiotherapy and Oncology</i> , 2009, 93, 402-407.	0.3	98
123	Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial. <i>Lancet</i> , The, 2009, 373, 301-308.	6.3	789
124	Improved accuracy and outcome in radiotherapy of lung cancer. <i>Radiotherapy and Oncology</i> , 2008, 87, 1-2.	0.3	12
125	Stereotactic body radiotherapy for medically inoperable patients with stage I non-small cell lung cancer " A first report of toxicity related to COPD/CVD in a non-randomized prospective phase II study. <i>Radiotherapy and Oncology</i> , 2008, 88, 359-367.	0.3	129
126	Image-guided adaptive radiotherapy " integration of biology and technology to improve clinical outcome. <i>Acta Oncologica</i> , 2008, 47, 1182-1185.	0.8	32



#	ARTICLE	IF	CITATIONS
127	Intrafraction changes of prostate position and geometrical errors studied by continuous electronic portal imaging. <i>Acta Oncologica</i> , 2008, 47, 1351-1357.	0.8	16
128	The normal tissue sparing potential of adaptive strategies in radiotherapy of bladder cancer. <i>Acta Oncologica</i> , 2008, 47, 1382-1389.	0.8	24
129	Accuracy of image-guided radiotherapy of prostate cancer based on the BeamCath® urethral catheter technique. <i>Radiotherapy and Oncology</i> , 2007, 83, 25-30.	0.3	11
130	Residual set-up errors and margins in on-line image-guided prostate localization in radiotherapy. <i>Radiotherapy and Oncology</i> , 2007, 85, 201-206.	0.3	44
131	FDG-PET Improves Management of Patients with Colorectal Liver Metastases Allocated for Local Treatment: A Consecutive Prospective Study. <i>Scandinavian Journal of Surgery</i> , 2007, 96, 209-213.	1.3	20
132	Aggravation of dyspnea in stage I non-small cell lung cancer patients following stereotactic body radiotherapy: Is there a dose-volume dependency?. <i>Acta Oncologica</i> , 2006, 45, 818-822.	0.8	36
133	Radical radiotherapy for urinary bladder cancer: treatment outcomes. <i>Expert Review of Anticancer Therapy</i> , 2006, 6, 269-279.	1.1	19
134	The emerging evidence for Stereotactic Body Radiotherapy. <i>Acta Oncologica</i> , 2006, 45, 771-774.	0.8	20
135	Phase II study on stereotactic body radiotherapy of colorectal metastases. <i>Acta Oncologica</i> , 2006, 45, 823-830.	0.8	379
136	Factors important for efficacy of stereotactic body radiotherapy of medically inoperable stage I lung cancer. A retrospective analysis of patients treated in the Nordic countries. <i>Acta Oncologica</i> , 2006, 45, 787-795.	0.8	220
137	Internal movement, set-up accuracy and margins for stereotactic body radiotherapy using a stereotactic body frame. <i>Acta Oncologica</i> , 2006, 45, 948-952.	0.8	34
138	Dummy run for a phase II study of stereotactic body radiotherapy of T1-T2 N0M0 medical inoperable non-small cell lung cancer. <i>Acta Oncologica</i> , 2006, 45, 973-977.	0.8	9
139	Dose-volume histograms associated to long-term colorectal functions in patients receiving pelvic radiotherapy. <i>Radiotherapy and Oncology</i> , 2005, 74, 203-210.	0.3	58
140	Phase-II study on stereotactic radiotherapy of locally advanced pancreatic carcinoma. <i>Radiotherapy and Oncology</i> , 2005, 76, 48-53.	0.3	323
141	Comparison of two dose calculation methods applied to extracranial stereotactic radiotherapy treatment planning. <i>Radiotherapy and Oncology</i> , 2005, 77, 96-98.	0.3	18
142	Treatment outcome and prognostic variables for local control and survival in patients receiving radical radiotherapy for urinary bladder cancer. <i>Acta Oncologica</i> , 2004, 43, 749-757.	0.8	19
143	Impact of changes in bladder and rectal filling volume on organ motion and dose distribution of the bladder in radiotherapy for urinary bladder cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2004, 59, 436-444.	0.4	103
144	Long-term bladder, colorectal, and sexual functions after radical radiotherapy for urinary bladder cancer. <i>Radiotherapy and Oncology</i> , 2004, 72, 139-145.	0.3	63

#	ARTICLE	IF	CITATIONS
145	Phase II Study of Vinorelbine in the Treatment of Platinum-Resistant Ovarian Carcinoma. <i>Gynecologic Oncology</i> , 2001, 81, 58-62.	0.6	52
146	Interaction between potential doubling time and TP53 mutation: predicting radiotherapy outcome in squamous cell carcinoma of the head and neck. <i>International Journal of Radiation Oncology Biology Physics</i> , 2001, 49, 519-525.	0.4	17
147	Dynamic cell cycle kinetics in vitro and in vivo in myelodysplastic syndromes with special reference to the influence of hematopoietic growth factors. <i>Leukemia Research</i> , 2000, 24, 999-1008.	0.4	1
148	Dynamic cell cycle kinetics of normal CD34+ cells and CD38+ subsets of haemopoietic progenitor cells in G-CSF-mobilized peripheral blood. <i>British Journal of Haematology</i> , 1999, 105, 1002-1013.	1.2	7
149	The effect of castration on tumour growth rate and cell kinetics in hormone-sensitive and hormone-insensitive rat prostatic adenomas. <i>Prostate Cancer and Prostatic Diseases</i> , 1999, 2, S29-S29.	2.0	0
150	The value of pretreatment cell kinetic parameters as predictors for radiotherapy outcome in head and neck cancer: a multicenter analysis. <i>Radiotherapy and Oncology</i> , 1999, 50, 13-23.	0.3	139
151	Optimization of a flow cytometric method for the simultaneous measurement of cell surface antigen, DNA content, and in vitro BrdUrd incorporation into normal and malignant hematopoietic cells. , 1998, 32, 28-36.		41
152	DNA ploidy and survival of patients with clinically localized prostate cancer treated without intent to cure. , 1998, 36, 244-249.		26
153	Lack of predictive value of potential doubling time and iododeoxyuridine labelling index in radiotherapy of squamous cell carcinoma of the head and neck. <i>Radiotherapy and Oncology</i> , 1998, 46, 147-155.	0.3	31
154	Importance of overall treatment time for the outcome of radiotherapy of advanced head and neck carcinoma: dependency on tumor differentiation. <i>Radiotherapy and Oncology</i> , 1997, 43, 47-51.	0.3	133
155	The relationship between tumor oxygenation and cell proliferation in human soft tissue sarcomas. <i>International Journal of Radiation Oncology Biology Physics</i> , 1996, 35, 701-708.	0.4	138
156	MIB1 expression and iododeoxyuridine labelling in soft tissue sarcomas: an immunohistochemical study including correlations with p53, bcl2 and histological characteristics. <i>Histopathology</i> , 1996, 28, 437-444.	1.6	17
157	Influence of sampling time on assessment of potential doubling time. <i>Cytometry</i> , 1994, 16, 144-151.	1.8	17
158	Nicotinamide pharmacokinetics in humans and mice: a comparative assessment and the implications for radiotherapy. <i>Radiotherapy and Oncology</i> , 1993, 27, 131-139.	0.3	83